AtheroGenics' ARISE Trial Results Published in The Lancet
23 Maggio 2008 - 2:55AM
Marketwired
ATLANTA, GA , a pharmaceutical company focused on the treatment
of chronic inflammatory diseases, today announced that The Lancet,
a peer-reviewed medical journal, will publish an article entitled,
"Effects of succinobucol (AGI-1067) after an acute coronary
syndrome: a randomized, double-blind, placebo-controlled trial," in
this week's May 24, 2008 issue. The article describes the results
from AtheroGenics' 6,144-patient ARISE outcome trial of its novel
diabetes drug candidate, AGI-1067.
"The ARISE trial has provided us with evidence that succinobucol
may be a promising new therapy, based on clinical activity in a
number of prespecified diabetes and cardiovascular endpoints,"
stated Dr. Jean-Claude Tardif, Co-Primary Investigator of the ARISE
study, director of the Montreal Heart Institute Research Centre and
professor of medicine at the Montreal Heart Institute and the
Universit� de Montr�al. "Although ARISE missed its primary endpoint
of reducing a composite of cardiovascular endpoints, we believe the
study data clearly indicate that succinobucol should be further
investigated to confirm its ability to improve glucose control in
patients with diabetes and to reduce cardiovascular events in
patients with heart disease."
Interested parties will be able to access this week's edition of
The Lancet by visiting their website on Saturday, May 24th, 2008 at
http://www.thelancet.com/. Once you access the website, click on
"This Week's Issue," and then click on "articles."
About AtheroGenics
AtheroGenics is focused on the discovery, development and
commercialization of novel drugs for the treatment of chronic
inflammatory diseases, including diabetes and coronary heart
disease (atherosclerosis). The Company's lead antioxidant and
anti-inflammatory drug candidate, AGI-1067, is being studied in a
Phase III clinical trial known as ANDES (AGI-1067 as a Novel
Anti-Diabetic Agent Evaluation Study), for the treatment of
diabetes. In addition, the Company has other clinical and
preclinical anti-inflammatory compounds, including AGI-1096, an
oral agent for the prevention of organ transplant rejection. For
more information about AtheroGenics, please visit
http://www.atherogenics.com.
Disclosure Regarding Forward-Looking Statements
Statements contained in this press release that relate to events
or developments that we expect or anticipate will occur in the
future are deemed to be forward-looking statements, and can be
identified by words such as "believes," "intends," "expects" and
similar expressions. AtheroGenics cautions investors not to place
undue reliance on the forward-looking statements contained in this
release. These statements are subject to certain factors, risks and
uncertainties that may cause actual results, events and
performances to differ materially from those referred to in such
statements. For example, additional information relating to the
safety, efficacy or tolerability of AGI-1067, may be discovered
upon further analysis of trial data. The U.S. Food and Drug
Administration might not allow us to conduct further studies of the
efficacy of AGI-1067 for the same or new endpoints, and, to the
extent approved, additional clinical trial work may take a
significant period of time to complete or require significant
additional resources to complete. We cannot ensure that AGI-1067
will ever be approved or be proven safe and effective for use in
humans. These and other risks are discussed in AtheroGenics'
Securities and Exchange Commission filings, including, but not
limited to, the risks discussed in AtheroGenics' Annual Report on
Form 10-K for the fiscal year ended December 31, 2007 and are
specifically incorporated by reference into this press release. We
undertake no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events,
or otherwise.
CONTACTS: AtheroGenics, Inc. Mark P. Colonnese Executive Vice
President 678-336-2511 Email Contact Media Inquiries Jayme Maniatis
/ Dana Conti Schwartz Communications, Inc. 781-684-0770 Email
Contact Investor Inquiries Lilian Stern Stern Investor Relations,
Inc. 212-362-1200 Email Contact
Grafico Azioni KraneShares Artificial I... (NASDAQ:AGIX)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni KraneShares Artificial I... (NASDAQ:AGIX)
Storico
Da Set 2023 a Set 2024